Drug
mecasermin
mecasermin is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_1
2
50%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
N/A1 (25.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_2
Long-Term Treatment With rhIGF-1 in GHIS
NCT00571727
completedphase_1
Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack
NCT01438086
terminatedphase_1
Effects of IGF-I in HIV Metabolic Disease
NCT01329744
completednot_applicable
IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients
NCT01446783
Clinical Trials (4)
Showing 4 of 4 trials
NCT00571727Phase 2
Long-Term Treatment With rhIGF-1 in GHIS
NCT01438086Phase 1
Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack
NCT01329744Phase 1
Effects of IGF-I in HIV Metabolic Disease
NCT01446783Not Applicable
IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4